QIAGEN powered by

Webinars and events

« All Events

  • This event has passed.

Investigating genomic variants using QIAGEN CLC Genomics Workbench, QCI Interpret-Translational (QCII-T), and QIAGEN Ingenuity Pathway Analysis (IPA)

July 18, 2023 @ 1:00 pm - 2:30 pm

Discovering new genes implicated in hereditary diseases or cancer progression is challenging yet advancing rapidly due to the increase in next-generation sequencing (NGS) cohort data. These data analyses produce insights into associations between gene variants and diseases and the biological mechanisms of these gene variants.

By combining QIAGEN CLC Genomics Workbench, QCII-T and QIAGEN IPA, you can analyze sequencing data obtained from a variety of NGS technologies, annotate gene variants using the world’s most comprehensive and up-to-date curated scientific evidence and find biological connections in gene variants with manually curated scientific findings. Using a streamlined NGS analysis workflow, you’ll get valuable and reliable insights for your research project and speed up your discoveries.

In this training, you’ll:
1. Learn to import whole genome or exosome sequencing data into QIAGEN CLC Genomics Workbench and use the ultra-fast LightSpeed Module that delivers an end-to-end NGS FASTQ to VCF pipeline
2. Explore the capabilities in QCII-T which can help accelerate your discoveries from hereditary or tumor cohort analyses to find associations between gene variants and diseases
3. Learn how to use QIAGEN IPA and its manually curated content, among other integrated scientific evidence, to uncover novel biological mechanisms underlying these gene variants

Register for event

Details

Date: July 18, 2023
Time:
 1:00 pm - 2:30 pm
Register for event

Venue:

Virtual – Americas – EST
United States
View Venue Website
Event Categories:
,
Event Tags:
, , ,

Venue

Virtual – Americas – EST
United States

Related Events

Register for event

On-demand Webinars


  • Indication expansion and drug repurposing using QIAGEN OmicSoft and Ingenuity Pathway Analysis

    Research and development for new drugs and disease treatments can be lengthy and costly. Indication expansion can help broaden the impact of a new drug that has already been through the arduous R&D process for a disease or cancer. Drug repurposing can take this concept and expand on it by looking for other diseases with similar drug target biology. The logic is if...

    WATCH NOW
  • Part I: Single-cell RNA sequencing data analysis using QIAGEN CLC Genomics Workbench

    This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. This session is for part I of this training. In this session, you'll learn to use QIAGEN CLC Genomics Workbench to perform se...

    WATCH NOW
  • Part II: Single-cell RNA sequencing data interpretation using QIAGEN Ingenuity Pathway Analysis

    This two-part series will walk you through single-cell RNA sequencing (scRNA-seq) analysis starting with a matrix file or FASTQ files and ending with a deep understanding of key pathways, regulators and cell type signatures within your data. In this session, we'll explore how you can take your scRNA-seq differential expression results produced from QIAGEN CLC Genom...

    WATCH NOW
  • Immune repertoire analysis using QIAGEN CLC Genomics Workbench

    The composition of the immune repertoire, consisting of the T cell and B cell receptors (TCR and BCR), is important for an organism's adaptive immune system and plays a pivotal role in an individual's overall health. Understanding the complex array of TCR and BCR allows for developing precision medicine and immunotherapy. Analyzing next-generation sequencing (NGS) dat...

    WATCH NOW
  • Compare and contextualize your results using QIAGEN Ingenuity Pathway Analysis

    Take your QIAGEN Ingenuity Pathway Analysis (IPA) analyses to the next level by comparing them to your own analyses (different time points, treatments, cell lines, diseases and more) or to a library of over 100K precomputed datasets to find similar or opposite biological signatures. Identify key genes or entities and then explore how they are expressed across normal t...

    WATCH NOW
  • Drug treatment, toxicology and target safety assessment using QIAGEN IPA and OmicSoft

    In this 90-minute training, you'll learn how to perform drug treatment, toxicology and target safety assessment-related discoveries using QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN Omicsoft Lands. Using public data from GTEx (normal tissue), GEO, cancer collections and more, you'll learn how to use Omicsoft Lands to: • Investigate a drug target or biom...

    WATCH NOW
Sample to Insight